Recombinant adeno-associated virus vectors (rAAV) are being explored as gene delivery
vehicles for the treatment of various inherited and acquired disorders. rAAVs are attractive …

Recombinant gene delivery vehicles based on adeno-associated virus (rAAV) have
emerged as promising vectors for the correction of genetic and acquired human disease …

Gene therapy with adeno-associated viral (AAV) vectors has reached the clinical stage for
many inherited and acquired diseases. However, due to a cargo capacity limited to< 5 kb …

Recombinant adeno-associated virus (rAAV) vectors are unique among the vector classes
currently available for human gene therapy in that they are based upon a class of viruses …

Adeno-associated virus (AAV) is one of the most promising viral gene transfer vectors that
has been shown to effect long-term gene expression and disease correction with low toxicity …

Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the
treatment of a variety of human diseases. Recent advances in developing clinically …

ADENO-ASSOCIATED VIRUS (AAV) VECTORS were first devel-oped 20 years ago (Carter,
2004) and an AAV vector was first administered to a human subject in November 1995 …

Adeno-associated virus (AAV) has emerged as an attractive vector for gene therapy. The
benefits of using AAV for gene therapy include long-term gene expression, the inability to …

Gene delivery vectors based on adeno-associated virus (AAV) are highly promising due to
several desirable features of this parent virus, including a lack of pathogenicity, efficient …

Recombinant adeno-associated virus (AAV)-based vectors expressing therapeutic gene
products have shown great potential for human gene therapy. One major challenge for …